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Over 80% of women with advanced breast cancer ultimately
develop bone metastases which account significantly for
morbidity and mortality. Breast cancer metastases in bone can
cause intractable pain, bone fracture, spinal cord compression and
hypercalcaemia. It also signifies that the malignant process is
incurable since, once tumour cells become lodged in the skeleton,
therapy can only be given with palliative intent. This includes
analgesics, radiation therapy and systemic treatments such as
hormone or chemotherapy. The events leading to the development
of bone lesions in patients with carcinoma of the breast are poorly
understood. However, histomorphometric studies have shown that
tumour cells are adjacent to actively resorbing osteoclasts (Boyde
et al, 1986) and it has been suggested that breast carcinoma cells
possess the capacity to recruit and stimulate osteoclasts by
producing stimulatory factors (Boyde et al, 1986). Parathyroid
hormone related peptide (PTHrP) is thought to be a major candi-
date factor produced by breast cancer cells which may promote
osteoclastic activity at metastatic sites in bone (Powell et al, 1991).
Bisphosphonates (BPs) are analogues of endogenous pyrophos-
phates in which a carbon atom replaces the central atom of
oxygen. In vivo, bisphosphonates bind strongly to hydroxyapatite
on the bone surface and are preferentially delivered to sites of
increased bone formation or resorption. They are potent inhibitors
of osteoclast-mediated bone resorption (Boonecamp et al, 1986)
and are effective in lowering serum calcium concentrations in
patients with hypercalcaemia of malignancy (Ryzen et al, 1985;
Kanis et al, 1987). Bisphosphonates are also used in the treatment
of Paget’s disease of bone (Altman et al, 1973; Plasmans et al,
1978) and bone lesions associated with multiple myeloma
(Berenson et al, 1996). The mechanisms by which bisphospho-
nates inhibit osteoclast-mediated bone resorption remain to be
determined, but may involve inhibition of formation of osteoclasts
from immature precursor cells (Boonecamp et al, 1986; Lowik
et al, 1988; Hughes et al, 1989) and/or direct inhibition of resorp-
tion via induction of apoptosis in mature osteoclasts (Lowik et al,
1988; Hughes et al, 1995; Selander et al, 1996). More recently,
several reports have indicated that bisphosphonates have direct
effects on other cell types which may have important implications
in the treatment of patients with cancer-induced bone disease.
Treatment with intravenous pamidronate (Hortobagyi et al, 1998)
and oral clodronate (Paterson et al, 1993) have been reported to
reduce the frequency of skeletal complications in established bone
disease. Oral clodronate has also been shown to decrease the
frequency of skeletal metastases in women who had recurrent
breast cancer but without bony involvement (Kanis et al, 1996).
Moreover, oral clodronate has recently been shown to increase
survival in women with breast cancer, when given at the time of
initial diagnosis to patients who have bone marrow micrometas-
tases at the time of surgery for their primary breast cancer (Diel
et al, 1998). However, other studies giving bisphosphonates in
either an adjuvant (Powles et al, 1998) or metastatic (Hortobagyi,
1998) setting have not demonstrated a survival benefit, and initial
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bone metastases (Wingen et al 1986; Hall and Stoica, 1994) with
no evidence of increased survival rates in vivo.
Bisphosphonates have been shown to have direct effects on
tumour cells in vitro, including the induction of apoptosis in
human myeloma cell lines (Shipman et al, 1997) and inhibition of
the adhesion of breast and prostate cancer cells to mineralized and
unmineralized bone matrix (Van der Plunijm et al, 1996; Boissier
et al, 1997). Furthermore, bisphosphonate treatment has been
shown to inhibit the progression and development of bone
metastases in a mouse model of breast cancer (Sasaki et al, 1995).
However, to date there have been no studies addressing the possi-
bility of a direct effect of bisphosphonates on growth, viability and
induction of apoptosis in human breast cancer cells. In the present
study we demonstrate that treatment of cultured human breast
cancer cells with the bisphosphonates zoledronate and
pamidronate leads to substantial loss of cell viability in concert
with key features of apoptosis.
MATERIALS AND METHODS
Reagents
Pamidronate (APD) (3-amino-1-hydroxy-propylidene-1,1-bisphos-
phonate) and zoledronate (1-hydroxy-2-[(1H-imidazole-1-yl)
ethylidene] 1-bisphosphonate) were obtained from Novartis
Pharmaceuticals Limited (Switzerland). EB 1053 (1-hydroxy-3-
(1-pyrrolidinyl)-propylidene-1,1-bisphosphonate) was a gift from
Dr Lise Binderup (Leo Pharmaceutical Products, Denmark) and
clodronate (dichloromethylene bisphosphonate) from Boehringer
Ingelheim, Finland.
The three amino bisphosphonates, pamidronate, EB 1053 and
zoledronate were dissolved in phosphate-buffered saline (PBS)
and clodronate was prepared in 0.04 mM sodium hydroxide.
[3H-methyl]-thymidine (80.0 Ci/mmol) was purchased from
Amersham International UK.
Tissue culture media Dulbecco’s modied Eagle’s medium
(DMEM) were obtained from Life Technologies (Paisley, UK).
BisBenzimide Trihydrochloride Hoechst 33258 (Sigma, Poole,
UK), was dissolved in PBS.
Cell cultures
MDA-MB-231, MCF-7 and Hs 578T human breast cancer cell
lines were maintained in DMEM supplemented with 100 U ml–1
penicillin, 100 mg ml–1 streptomycin and 5% fetal calf serum
(FCS) at a constant temperature of 37°C with a humidified atmos-
phere of 5% carbon dioxide (CO2). The cells were passaged once a
week. For growth experiments, cells were trypsinized and 1 ´ 104
cells were plated in 12-mm diameter wells (48-well plates) in
0.5 ml of the growth medium. The cells were cultured for 24 h
before treatment. Cells were treated with the bisphosphonates in
5% FCS with the above mentioned supplements for up to 7 days
without changing the medium. Control cultures were incubated in
medium containing vehicle alone.
Proliferation assay
A modification of the crystal violet assay was used to determine
breast cancer cell proliferation (Wosikowski et al, 1993). On
selected days after removal of the tissue culture medium, the cell
monolayer was fixed with methanol prior to staining with 0.5 ml
(48-well plates) of 0.5% crystal violet solution in 25% methanol
for 10 min. After washing several times with distilled water to
remove the excess dye, the cells were air dried for at least 20 h.
The incorporated dye was solubilized in 1 ml (48-well plates) of
0.1 M sodium citrate in 50% ethanol and 100 ml aliquots were
transferred to 96-well plates (Nunc Life Technologies, Paisley,
UK). In order to determine cell number in each sample, the optical
density (OD) was measured directly at a wavelength of 550 nm in
a microplate reader (Titertek Mutiskan). The OD of each sample
was then compared with a standard curve, in which the OD was
directly proportional to known cell numbers.
DNA fragmentation assay
Quantitation of DNA fragmentation in breast cancer cells was
undertaken following [3H]thymidine incorporation. This method
takes into account the observation that DNA which has undergone
extensive double-stranded fragmentation fails to sediment with
very large, chromosomal length DNA when subjected to centrifu-
gation.
Breast cancer cells were incubated with [3H-methyl]-thymidine
(0.1 mCi ml–1) for 9–16 h to label DNA and then washed before
exposure to the indicated treatment. Cells were lysed with lysis
buffer (10 mM Tris (pH 7.4), 10 mM ethylenediamine-tetraacetic
acid (EDTA) and 0.2% Triton X-100), and fragmented double-
stranded DNA was separated from chromosome-length unfrag-
mented DNA by centrifugation followed by trichloroacetic acid
(TCA) precipitation (Duke and Cohen, 1992). Incorporated radio-
label was determined by liquid scintillation counting using the
formula: % fragmented DNA = 100 ´ (fragmented/fragmented +
intact chromatin) (Duke and Cohen, 1992).
MTS assay
Cell viability was determined by 3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4-sulphophenyl)-2H-tetrazolium
(MTS) dye-reduction assay measuring mitochondrial respiratory
function (Cory et al, 1991). Breast cancer cells (1 ´ 103 well–1)
were plated in 96-well microtitre plates and treated with bisphos-
phonates at various concentrations and for different periods of
time. Cells were incubated with MTS dye (2 mg/ml per 20 ml
well–1) for 2 h and solubilized with 25 ml of 10% sodium dodecyl
sulphate (SDS) at room temperature for 4 h. Absorbance was
determined in a Titertek plate reader at 490 nm. The absorbance is
directly related to viable cell number.
Videomicroscopy
In order to further validate the induction of apoptosis by identi-
fying morphological features, time lapse videomicroscopy was
used to directly observe cell death. Hs 578T cells were plated in
T25 flasks with a cell density of 1 ´ 105 cells per flask for 24 h and
treated with 100 mM of pamidronate in PBS. Treated flasks were
photographed over a 72 h period at 1/150 normal speed with a
time-lapse videomicroscope.
Analysis of nuclear morphology
MDA-MB-231 and Hs 578T cells were seeded at a density of
1 ´ 104 cells per well in 2 ml chamber slides (Nunc). Cells were
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50 mM of zoledronate and grown in the presence of the bisphos-
phonates for 3 days. On the third day after removal of the tissue
culture medium, the cell monolayer was fixed with
methanol–acetic acid 3:1 (v/v) for 10 min before staining them
with Hoechst 33258 (1 mg ml–1) at 37°C in the dark. After 10 min,
coverslips were washed in distilled water and mounted in a
mounting medium (0.466 g of citric acid and 0.778 g of disodium
orthophosphate dissolved in 50 ml of distilled water added to 50
ml of glycerol) and examined using a universal microscope (Zeiss,
Germany) with UV illumination (Filter FT 395) equipped with an
MC 63 automatic photomicrographic camera (film speed of 17).
Apoptotic cells were defined on the basis of characteristic changes
in the nuclear morphology.
Western blotting for bcl-2 and Bax
MDA-MB-231 cell cultures were seeded in T125 flasks with a cell
density of 5 ´ 106 for 24 h before they were exposed to vertical and
100 mM pamidronate for 1, 2, 3 and 4 days and were then harvested
and lysed in lysis buffer (50 mM Tris–HCl, 150 mM sodium chlo-
ride (NaCl), pH 8.0, with 0.1% Triton X-100, 0.01 mg ml–1 apro-
tinin and 0.05 mg ml–1 phenylmethylsulphonyl fluoride (PMSF),
Sigma, Poole, UK). Equivalent protein extracts (15 mg) from each
sample were electrophoresed on 10% sodium dodecyl sulphate
polyacrylamide gel electrophores (SDS-PAGE) mini gels. Total
protein was quantitated by the method of Bradford (1976) and
equivalent loading was confirmed by Coomassie blue staining of
replicate gels. Proteins were transferred onto Hybond C-Super
nitrocellulose (Amersham International, UK) in a Bio-Rad Trans
blot apparatus. Nitrocellulose matrices were preblocked with 5%
non-fat milk powder in PBS and 0.05% Tween-20 for 1 h at room
temperature. Following PBS–Tween washes, preblocked matrices
were incubated with 2 mg ml–1 equivalent of mouse monoclonal
antibodies against bcl-2 giving a protein band at 28 kDa or rabbit
polyclonal antibodies to bax giving a band at 21 kDa (Santa Cruz,
Heidelberg, Germany). Bcl-2 and bax were detected by horse-
radish peroxidase-conjugated secondary antibodies to anti-mouse
and anti-rabbit immunoglobulins respectively (Amersham Inter-
national) for a 1 h incubation at room temperature and visualizing
specific bands by enhanced chemiluminescence (ECL, Amersham
International). Densitometry was performed on a Microtek
Scanmaker IISP flat bed scanner and quantitated with NIH Image
1.52 software.
Western blotting for PARP
MDA-MB-231 breast cancer cells (5 ´ 106) were seeded in T125
flasks for 24 h before being exposed to 100 mM pamidronate,
100 mM zoledronate or vehicle (PBS) for up to 72 h. Cells were
then harvested and washed once with cold PBS and lysed in 100 ml
of lysis buffer (20 mM Tris, 40 mM sodium phosphate, 50 mM
sodium fluoride, 5 mM magnesium chloride, 10 mM ethylene
glycol-bis(b-aminoethyl ether) N,N,N¢,N¢-tetraacetic acid
(EGTA), 0.5% sodium deoxycholate, 1% Triton X-100, 0.1%
SDS, 40 mg ml–1 leupeptin, 100 mg ml–1 aprotinin, 20 mg ml–1
PMSF in DMSO and 50 mM sodium orthovanadate) for 30 min on
ice. Equivalent protein extracts (17 mg) from each sample were
electrophoresed on 10% SDS-PAGE mini gels. After transferring
the proteins onto Hybond C-Super nitrocellulose matrices
(Amersham International) and preblocking with 5% non-fat milk
powder in PBS and 0.05% Tween-20 as in the above mentioned
protocol, membranes were incubated with 2 ml ml–1 equivalent of
rabbit polyclonal antibodies to PARP (Boehringer Mannheim,
GmbH, Germany) and detected by horseradish peroxidase-conju-
gated secondary antibodies to anti rabbit immunoglobulins.
Specific bands were visualized by ECL (Amersham International).
Densitometry was performed on a Microtek Scanmaker IISP flat
bed scanner and quantitated with NIH Image 1.52 software.
Statistical analysis
Statistical analysis was performed by unpaired Student’s t-test or
analysis of variance (ANOVA) using Statview software package
for the Apple Macintosh (Abacus Concept, Inc., Berkeley, CA,
USA). P-values were *P < 0.001 and **P < 0.0005.
RESULTS
Bisphosphonates decrease breast cancer cell number
With MDA-MB-231 breast cancer cells, treatment with 100 mM
pamidronate and 500 mM EB1053 produced a significant reduction
in cell number which was apparent at day 5 and maintained up to
day 7 of treatment (Figure 1). This experiment revealed that both
bisphosphonates produced a significant inhibition of cell growth
relative to control cultures: 83% inhibition with 100 mM
pamidronate and 58% with 500 mM EB 1053 by day 5. Similar
inhibition of cell growth was seen in MCF-7 and Hs 578T cells
treated with 100 mM of pamidronate (70% and 85% respectively,
relative to control cultures at day 6).
Bisphosphonates reduce breast cancer cell viability
In order to determine if reduction in cell number with bisphospho-
nate treatment was associated with loss of cell viability, MCF-7,
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Figure 1 Effects of pamidronate (APD) and EB 1053 on cell growth of
MDA-MB-231 cells. Cells were treated for up to 7 days with 100 mM APD or
500 mM of EB 1053 without renewing the medium. Cells were plated at a
density of 1 ´ 104 per well in 48-well plates. On selected days cell
monolayers were stained with crystal violet dye and absorbance at 550 nm
determined as described in Materials and MethodsHs 578T and MDA-MB-231 cells were incubated for 4 days with
four bisphosphonates, pamidronate, EB1053, clodronate and zole-
dronate (2–2000 mM) and cell viability was determined by MTS
dye reduction assay. The order of potency of the four bisphospho-
nates was similar in all three breast cancer cell lines. Zoledronate
was the most potent compound with 50% inhibition of cell
viability relative to control cultures obtained in the presence of
15 mM of the bisphosphonate in MDA-MB-231 cells, 20 mM in
MCF-7 cells and 3 mM in Hs 578T cells. Pamidronate was less
potent than zoledronate with 50% inhibition of cell viability rela-
tive to control cultures obtained in the presence of 40 mM of the
bisphosphonate in MDA-MB-231 cells, 35 mM in MCF-7 cells and
25 mM in Hs578T. Clodronate and EB1053 were both less effective
than zoledronate and pamidronate, inducing 50% inhibition in
MDA-MB-231 cells at 700 mM and 1000 mM, in Hs578T cells at
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Figure 2 Effects of zoledronate, pamidronate (APD), clodronate and EB
1053 on viability of (A) MCF-7 cells, (B) Hs 578T cells and (C) MDA-MB-231
cells. Cells were treated in with increasing concentrations of bisphosphonates
for 4 days. Cell viability was quantitated using MTS dye reduction assay
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Figure 3 (A) To determine the minimum time of exposure to
bisphosphonates required to observe loss of cell viability, MDA-MB-231 cells
were exposed to 100 mM of pamidronate (APD, hatched bars) or for 24, 36 or
96 h at which time the medium was removed and fresh medium without
bisphosphonates was added. Cell viability was measured on day 4, and
compared with cultures incubated in the absence of bisphosphonate for 4
days (control, solid bars). (B) To determine if bisphosphonates have any
effects on cell viability of normal cells, 3T3 mouse embryo fibroblast cells
were treated with 10, 50 100 mM of zoledronate for 3 days (n n). To determine
whether the direct effects of bisphosphonates on loss of cell viability in breast
cancer cells could be due to calcium chelating properties of these
compounds, MDA-MB 231 cells were treated with 10, 50 and 100 mM of
EDTA for 3 days (l) and equal concentrations of zoledronate (l l). Cell
viability was quantitated by MTS dye reduction assay
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3T3/Zoledronate900 mM and >2000 mM and in MCF-7 cells at 2000 mM and 
>2000 mM respectively (Figure 2 A–C). In order to identify the
minimum time of exposure to bisphosphonates required to observe
loss of cell viability at day 4, MDA-MB-231 cells were exposed to
100 mM pamidronate for 24, 36 and 96 h, then medium removed
and fresh medium containing no bisphosphonate was added for the
remainder of the 4-day incubation period. The results demon-
strated that the presence of pamidronate for only 24 h leads to irre-
versible loss of cell viability at 4 days (Figure 3A). To determine if
bisphosphonates have any direct effect on normal cells other than
breast cancer cells, 3T3 mouse embryo fibroblasts cells were
exposed to 10, 50 and 100 mM zoledronate for up to 3 days. The
results demonstrate that by day 3 there is not a significant loss of
cell viability in 3T3 cells compared to control (Figure 3B).
To determine whether the direct effects of bisphosphonates on
reduction of cell viability in breast cancer cells could be due to
calcium chelating properties of these compounds, MDA-MB-231
cells were treated with 10, 50 and 100 mM of EDTA and cell
viability was compared to cultures treated with these same concen-
trations of zoledronate for 3 days (Figure 3B). The results showed
that even though treatment with 100 mM of zoledronate reduced
MDA-MB-231 cell viability significantly, there was not a signifi-
cant reduction in cell viabililty with 100 mM of EDTA.
Bisphosphonates induce apoptosis in human breast
cancer cells
Identification of apoptosis through changes in
morphological features
Videomicroscopy was used to confirm that the time-dependent
loss in cell viability in cultures of breast cancer cells treated with
bisphosphonates was accompanied by morphological changes
consistent with induction of apoptosis. Hs 578T cells grown in
T25 flasks were incubated in medium containing 100 mM
pamidronate for up to 72 h. After 24 h, characteristic morpholog-
ical features of apoptosis were observed including detachment and
cell shrinkage. These features were even more marked at 48 and 
72 h (Figure 4).
Changes in nuclear morphology
Pamidronate (100 mM) and zoledronate (50 mM) treatment for 3
days caused changes in nuclear morphology consistent with
induction of apoptosis in MDA-MB-231 cells and Hs 578T cells
respectively. When stained with Hoechst 33258, many of the
MDA-MB-231 and Hs 578T cells had nuclei that were brightly
stained and with separate globular structures (Figure 5) compared
to untreated cells which had rounded intact nuclei. These features
are highly characteristic of apoptotic cells (Wyllie, 1980). Similar
changes in nuclei were seen with Hs 578T cells treated with
pamidronate (100 mM) (not shown).
Quantitation of DNA fragmentation
A key feature of apoptosis in many cell types is induction of
genomic DNA fragmentation which arises from activation of
endogenous endonucleases (Wyllie, 1980; McConkey et al, 1996).
MDA-MB-231 cells treated with pamidronate (100 mM) demon-
strated a time-related increase in the proportion of fragmented
DNA which was 4.5-fold control levels at day 2 and greater than
six times control levels at day 3 (Figure 6A). Similar increases in
the proportion of fragmented DNA were also detected in Hs578T
and MCF-7 cells treated for 2 days with 100 mM pamidronate
Bisphosphonates and breast cancer 1463
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Figure 4 Morphological changes of apoptosis in Hs 578T cells treated with 100 mM pamidronate (APD) Hs 578T cells were seeded into T25 tissue culture
flasks and treated for (A) 0 h, (B) 24 h, (C) 48 h and (D) 72 h with pamidronate (APD). Cultures were photographed over 72 h period by time lapse
videomicroscopy
D C
B A(Table 1). Results are comparable to those obtained with tumour
necrosis factor a (TNF-a) (20 ng ml–1 for 2 days) and cell-perme-
able C2 ceramide (20 mM for 3 days), both of which have been
shown to induce apoptosis in breast cancer cells (Dbaibo et al,
1997). To compare the effects of zoledronate with pamidronate on
DNA fragmentation, Hs 578T cells were treated with zoledronate
or pamidronate (10, 50 and 100 mM) for 3 days. Marked induction
of DNA fragmentation was seen with zoledronate with 3.6-fold
increase in fragmented DNA compared to control at 10 mM (47%
vs 13% fragmented DNA) while this concentration of pamidronate
did not induce DNA fragmentation. With 100 mM zoledronate,
84% DNA fragmentation (6.4-fold increase compared to control)
was seen compared to 32% (2.4-fold) with pamidronate. To assess
the effects of the two other bisphosphonates on induction of DNA
fragmentation, both Hs 578T and MCF-7 cells were treated with
clodronate and EB1053 (both at 500 mM and 2000 mM). In Hs578T
cells, treatment with clodronate at the lower concentration induced
a 2.7-fold increase in DNA fragmentation compared to controls
while a 5.6-fold increase was observed with the higher concentra-
tion. No induction of DNA fragmentation was observed with
EB1053 in this cell line. In MCF-7 cells, substantial induction
(5.6-fold) of DNA fragmentation was seen only with the higher
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Figure 5 Fluorescence micrographs of the nuclei of MDA-MB-231 and Hs
578T cells following treatment with 100 mM of pamidronate (APD) and 100 mM
zoledronate respectively for 3 days. Nuclei were stained with Hoechst 33258
and examined under a universal microscope with UV illumination (´600
magnification). Apoptotic nuclei are marked with arrows
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Figure 6 (A) Effects of pamidronate on DNA fragmentation in human breast
cancer cell line MDA-MB-231. Cells were treated for up to 3 days with 100 mM
of pamidronate (APD). Percentage of DNA fragmentation in treated cells
(hatched bars) are compared with that in control cells (solid bars). 
(B) Comparing the effects of zoledronate and pamidronate on induction of
DNA fragmentation. Hs 578T cells were treated with 10, 50 and 100 mM of
zoledronate and pamidronate (APD) for 3 days. Percentage of DNA
fragmentation in cells treated with zoledronate (dotted bars) are compared
with that of cells treated with APD (hatched bars)
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Table 1 Effects of bisphosphonates on induction of DNA fragmentation in
human breast cancer cells
Concentration (mM) DNA fragmentation (%)
Hs 578T
Control 0 12.95 ± 0.55
Pamidronate 100 32.1 ± 2.45**
Control 0 2.97 ± 0.56
EB 1053 500 3.85 ± 0.34
2000 5.92 ± 0.46
Control 0 7.66 ± 0.04
Clodronate 500 20.90 ± 0.33**
2000 43.25 ± 4.09**
Ceramide 20 22.00 ± 1.95**
MCF-7
Control 0 4.80 ± 1.96
Pamidronate 100 16.11 ± 1.19**
Control 0 3.37 ± 0.38
EB 1053 500 3.75 ± 0.78
2000 7.74 ± 2.50**
Control 0 3.53 ± 0.53
Clodronate 500 6.20 ± 0.22
2000 17.76 ± 1.08**
TNF-a 0.0012 23.05 ± 1.11**
MDA-MB-231
Control 0 2.95 ± 0.54
Pamidronate 100 19.30 ± 1.55**
Zoledronate 100 24.61 ± 3.1**
Hs 578T cells were treated for 72 h and MCF-7 cells for 96 h with
pamidronate (100 mM), EB1053 or clodronate (500 and 2000 mM). MDA-MB-
231 cells were treated for 72 h with 100 mM pamidronate or 100 mM
zoledronate. Percentage of DNA fragmentation in cells treated with
bisphosphonates are compared with that of control (vehicle-treated) cells.
Level of DNA fragmentation in Hs 578T cells was compared with that
induced by cell-permeable C2 ceramide, a known inducer of apoptosis. DNA
fragmentation levels in MCF-7 cells were compared with TNF-a-treated
cultures; **P < 0.0005.concentration of clodronate after 4 days of treatment. Treatment
with EB1053 at this same high concentration induced a 2.5-fold
increase in DNA fragmentation (Table 1).
Effects of pamidronate on expression of bcl-2 and bax
A number of genes and proteins are implicated in the regulation of
apoptosis (Golstein, 1997). It has been demonstrated that the bcl-2
gene product confers resistance to apoptosis induced by a number
of stimuli (Reed, 1994) whilst its homologue, bax, promotes apop-
tosis (Oltvai et al, 1993). The ability of bcl-2 and bax to form
heterodimers suggests that the susceptibility of a cell to undergo
apoptosis depends in part on the ratio of bcl-2 to bax, with a lower
ratio favouring apoptosis (Boise et al, 1993). To assess the effects
of bisphosphonate treatment of breast cancer cells on expression of
these oncoproteins, MDA-MB-231 cells were treated for up to 4
days with 100 mM pamidronate, and the levels of expression of bcl-
2 and bax proteins were determined by Western analysis. Figure
7A and B depicts the regulation of bcl-2 and bax protein levels
respectively by pamidronate over a period of 1–4 days. A progres-
sive reduction in bcl-2 protein with time of pamidronate (100 mM)
treatment was observed. In contrast, there was no marked regula-
tion in bax protein. Figure 7C shows the densitometric results from
Western blots presented as bcl-2/bax ratio. In control cells there
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Figure 7 Effects of pamidronate on expression of (A) bcl-2 and (B) bax.
MDA-MB-231 cells were treated for up to 4 days with pamidronate (APD)
(100 mM), before cell extracts were prepared and Western blot analysis
carried out. Lane order: (1) control and (2) APD. (C) Corresponding
densitometric analysis of bcl-2 and bax protein levels expressed as bcl-2/bax
ratios for each time of treatment
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Figure 8 (A) Time-dependent proteolytic degradation of PARP in MDA-MB-
231 cells treated with 100 mM pamidronate (APD) for up to 3 days. Lanes 1–4
show the proteolytic degradation of 116 kDa full-length PARP to a 30 kDa
fragment with time. (B) Corresponding densitometric analysis of 30 and 116
fragment levels, expressed as 30/116 ratio, with time. (C) Comparison of the
proteolytic cleavage of PARP in MDA-MB-231 cells treated with or without
100 mM pamidronate and 100 mM zoledronate for 60 h. Lane order: 
(1) control, (2) 100 mM pamidronate and (3) 100 mM zoledronatewas little change in bcl-2/bax ratio over the time of culture with
ratios ranging from 0.93 at day 1 to 1.1 at day 4. In contrast,
cultures of MDA-MB-231 exposed to pamidronate demonstrated a
progressive decline in bcl-2-bax ratio reaching 0.57 at day 4 (50%
of control).
Poly (ADP)-ribose polymerase (PARP) cleavage
Proteolytic cleavage of PARP as a consequence of activation of
cell death proteases (caspases) is another key feature of apoptosis
(Kaufmann et al, 1993; Lazebnik et al, 1994; Tewari et al, 1995).
Full-length PARP is a 116 kDa molecule which is cleaved by the
action of CPP32 (caspase 3) and related caspases to fragments of
85 and 30 kDa. PARP cleavage consistent with caspase activation
was observed in extracts of MDA-MB-231 cells incubated with
100 mM pamidronate. Cells were incubated with the bisphospho-
nate for up to 72 h and cleavage of the 116 kDa molecule was
determined by immunoblotting utilizing a polyclonal antibody
which recognizes the intact form and 30 kDa fragment. These
studies demonstrated a time-related decrease in the 116 kDa intact
PARP and an appearance of the 85 and 30 kDa fragment. By 72 h
of treatment there was a virtual disappearance of the 116 kDa
species and an appearance of a strong band corresponding to the
30 kDa cleaved product (Figure 8A). Figure 8B shows the densit-
ometric results from these Western analyses presented as the ratio
of 30–116 kDa species. Extracts of MDA-MB-231 cultures which
had been exposed to 100 mM pamidronate demonstrated an
increase with time of treatment in the 30/116 kDa ratio from 0.51
at 18 h to 9.07 at 72 h. Figure 8C shows a comparison of PARP
cleavage in MDA-MB-231 cells treated with 100 mM pamidronate
and 100 mM of zoledronate. Both treatments lead to an appearance
of the 30 kDa cleavage product which is absent in control cultures.
DISCUSSION
Our study provides the first evidence that bisphosphonates can
directly induce apoptosis in cultured human breast cancer cell
lines. Clodronate and three amino bisphosphonates, pamidronate,
EB1053 and zoledronate, reduced cell viability in three human
breast cancer cell lines, MDA-MB-231, MCF-7 and Hs 578T.
These results are consistent with earlier reports that bisphospho-
nates can inhibit cell proliferation and induce apoptosis in
osteoclasts (Hughes et al, 1995; Selander et al, 1996), J774
macrophage-like cells (Selander et, al 1996) and myeloma cells
(Shipman et al, 1997). Exposure of MDA-MB-231 cells to
pamidronate led to a decrease in cell number that was found to be
time- and concentration-related. These effects on cell number
could result from either decreased proliferation or increased cell
death. Demonstration of a decrease in viability of MDA-MB-231,
MCF-7 and Hs 578T cells treated with all four bisphosphonates
confirms that the reduction in cell number is due to enhanced cell
death. Zoledronate was more effective in each of the three cell
lines with 50% reduction in cell viability compared to control
cultures achieved at 15, 20 and 3 mM, followed by pamidronate at
40, 35 and 25 mM respectively in MDA-MB-231, MCF-7 and Hs
578T cultures after 4 days of treatment. In contrast clodronate was
less effective in all three cell lines with 50% reduction in cell
viability compared to control cultures achieved at 700, 2000 and
900 mM. This is also in contrast to previous report (Busch et al,
1998) that clodronate is able to reduce cell survival of MDA-MD-
435S cells but not MCF-7 cells. Time lapse videomicroscopy
showed a time-dependent increase in the proportion of Hs 578T
breast cancer cells having the morphological features character-
istic of apoptotic cell death when treated with 100 mM
pamidronate. This is futher confirmed by the characteristic
changes in morphological features of the nucleus stained with
Hoechst staining in MDA-MB-231 cells and Hs 578T cells treated
with 100 mM of pamidronate and 50 mM of zoledronate respec-
tively for 3 days. A characteristic feature of apoptosis is activation
of endogenous endonucleases, resulting in fragmentation of
genomic DNA (Wyllie, 1980; McConkey and Orrenius, 1996).
Treatment of MDA-MB-231 breast cancer cells with 100 mM
pamidronate resulted in a time-related increase in DNA fragmen-
tation which reached approximately six-fold compared to control
by day 3 of treatment. In addition, substantial induction of DNA
fragmentation by this concentration of pamidronate was also iden-
tified in two other breast cancer cell lines, Hs 578T and MCF-7,
and levels were comparable to those achieved with two known
inducers of apoptosis, cell-permeable C2 ceramide and TNF-a
(Dbaibo et al, 1997). Direct comparison of the two bisphospho-
nates pamidronate and zoledronate in inducing DNA fragmenta-
tion shows that zoledronate is the more potent bisphosphonate
with a substantial increase in fragmented DNA levels, at concen-
trations as low as 10 mM. This finding is consistent with the
observed potency in reducing cell viability.
The concentrations of pamidronate used in our studies are
equivalent to those that Shipman et al (1997) reported to be
required to cause apoptosis in human myeloma cell lines.
Clodronate was found to induce apoptosis (as determined by DNA
fragmentation) in both MCF-7 and Hs578T cells but only at
concentrations above 500 mM. The novel bisphosphonate EB1053
induced DNA fragmentation only in MCF-7 cells and at 2000 mM.
Differences in potency could indicate that these compounds are
mediating effects on apoptosis via alternate signalling pathways or
could be related to differences in bioavailability and cellular
uptake of the bisphosphonates. It has been demonstrated that lipo-
some-encapsulated clodronate is 300 times more potent than the
free bisphosphonate in inducing apoptosis in J774 macrophage-
like cells (Frith et al, 1997). All bisphosphonates bind to hydroxy-
apatite by virtue of their carbon-substituted pyrophosphate
structure and this accounts for their selective action on the
skeleton. They are rapidly taken up into bone; in animal studies it
has been shown that skeletal uptake of alendronate reaches 90% of
peak values within 1 h of intravenous or oral administration (Lin et
al, 1991). Although concentrations of 10 mM zoledronate and up to
100 mM pamidronate were required to cause breast cancer cell
apoptosis in our study, it has been suggested that the pharmacolog-
ical concentrations of bisphosphonates required to inhibit bone
resorption could lead to exposure of osteoclasts to even higher
concentrations in vivo. Sato et al (1991) have concluded that the
local concentration of bisphosphonate released from hydroxy-
apatite into the resorption space would be substantially higher than
that present in the circulation and could reach 1000 mM. While
osteoclasts are the cells most likely to be exposed to these rela-
tively high concentrations of bisphosphonates during resorption of
bone, it is possible that the close association of breast cancer cells
with actively resorbing osteoclasts within lytic lesions will also
result in exposure of the tumour cells to levels of bisphosphonates
sufficient to induce apoptosis. Our findings indicate that the order
of bisphosphonate potency on bone resorption is not equivalent to
that for induction of apoptosis in breast cancer cells. It is cell type-
specific. Zoledronate is reported to be 100 times more potent than
pamidronate in reducing bone resorption (Fleisch, 1997) and our
1466 SG Senaratne et al
© 2000 Cancer Research Campaign British Journal of Cancer (2000) 82(8), 1459–1468study suggests it is up to tenfold more potent than pamidronate in
inducing apoptosis in breast cancer cells. EB1053, which is 100
times more potent than pamidronate in inhibiting bone resorption
in rats (Fleisch, 1997), was substantially less effective on breast
cancer cells. DNA fragmentation in response to EB1053
(2000 mM) was detected only in MCF-7 cells, although both Hs
578T and MDA-MB-231 cells were growth inhibited by this agent
at the same high concentration.
The mechanism by which zoledronate, pamidronate and other
bisphosphonates induce apoptosis in breast cancer cells is not
clear. Effects may be related to decreased cell adhesion since
pretreatment of MDA-MB-231 and MCF-7 breast cancer cells and
also pretreatment of bone slices with, pamidronate, clodronate or
ibandronate for 24 h prevents attachment and spreading of cells
onto bone slices (van der Pluijm et al, 1996; Boissier et al, 1997).
While the relationship of this observation to integrin expression
has not been fully elucidated (Boissier et al, 1997) it has been
demonstrated that inhibition of integrin anb3 production can
induce apoptosis in MDA-MB-231 breast cancer cells (Townsend
et al, 1997). Our present results clearly demonstrate that treatment
of MDA-MB-231 breast cancer cells with pamidronate leads to a
time-dependent induction of PARP cleavage implicating a
caspase-dependent signalling pathway. It is well established that
PARP is a death substrate for the caspase-3 family of death
proteases (caspase -3, -6 and -7) (Lazebnik et al, 1994; Tewari et
al, 1995). Our findings are in agreement with recent studies by
Coxen and associates (Coxen et al, 1998) who have reported 
that induction of apoptosis in J774 macrophage-like cells by
alendronate is associated with caspase-3-like activity. Since the
caspase-3 family members are substrates for upstream caspases
such as caspase-8 and caspase-9, further studies are required to
identify which of these death proteases play a major role in the
apoptosis signalling pathway induced by bisphosphonates.
Changes in mitochondrial function induced by different apoptotic
stimuli are associated with release of cytochrome c into the cytosol
resulting in the activation of caspases (Bossy-Wetzel, et al, 1998;
Cardone et al, 1998). It has been suggested that bcl-2 prevents the
release of cytochrome c into the cytosol (Marzo et al, 1998)
thereby inhibiting the activation of caspases. Therefore, the ability
of pamidronate to down-regulate bcl-2 expression further suggests
the involvement of caspase activation with changes in mitochon-
drial function in this pathway. Luckman and colleagues have
reported that aminobisphosphonates induce apoptosis in a mouse
macrophage cell line via inhibition of the mevalonate pathway and
inhibition of protein prenylation (Luckman et al, 1998). A similar
pathway has been identified for induction of apoptosis in human
myeloma cells by YM 175 (Shipman et al, 1998). More recent data
have shown that prenyltransferase inhibitors such as lovastatin can
induce apoptosis in proliferating thyroid cells through a p53-inde-
pendent, CrmA-sensitive and caspase-3 like protease-dependent
mechanism (Vitale et al, 1999). The relationship of this finding to
effects of bisphosphonates on protein prenylation and induction of
apoptosis in breast cancer cells warrants further investigation.
However clodronate, which is a non-amino bisphosphonate, may
inhibit viability of macrophage-like cells by an alternate mecha-
nism involving incorporation into non-hydrolysable analogues of
ATP (Frith et al, 1997).
Taken together these various laboratory studies suggest that
bisphosphonates may reduce tumour burden in bone by a variety
of mechanisms which include modulation of bone-derived tumour
growth factor release (Mundy and Yoneda, 1998), and effects on
breast cancer cell attachment as well as direct effect on cell
viability. Besides the inhibitory effects of bisphosphonates on
tumour-induced osteoclastic resorption, this previously unrecog-
nized direct effect on breast cancer cell viability make them suit-
able for pharmacological interventions in patients with breast
cancer. Our finding that bisphosphonates, including clodronate,
can induce apoptosis in breast cancer cells may relate to recently
reported clinical findings that clodronate reduces tumour burden in
bone and in soft tissue with a consequent improvement in survival
(Diel et al, 1998). There is a discrepancy between this report and
other randomized studies evaluating bisphosphonates. This may be
because the patients in the Diel study were highly selected by
virtue of the presence of bone marrow micrometastases detected
immunocytochemically (that is, without clinical or radiological
evidence of disease) when the tumour burden would have been
very low. The median follow-up at the time of publication was
only 36 months and thus the long-term outcome is awaited with
interest. Moreover the technique of bone marrow sampling is not
widely used. Thus additional or alternative markers for predicting
the development of bony metastases need to be explored in
conjunction with the underlying mechanisms involved. It is note-
worthy that in our current study zoledronate induces a greater
degree of apoptosis and at least theoretically may have a more
potent effect on survival if given in early breast cancer. Thus the
development of the new, more potent third-generation bisphospho-
nates may offer the opportunity of further improving the morbidity
and survival of patients with both early and advanced breast
cancer. Therefore in vivo studies are required to evaluate these
newer agents both in terms of patient groups who would be
expected to be benefit as well as duration of the treatment and
potential impact on survival.
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